Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer
Authors
Grose, William E.Clark, K. Reed
Griffin, Danielle
Malik, Vinod
Shontz, Kimberly M.
Montgomery, Chrystal L.
Lewis, Sarah
Brown, Robert H. Jr.
Janssen, Paul M. L.
Mendell, Jerry R.
Rodino-Klapac, Louise R.
UMass Chan Affiliations
Department of NeurologyDocument Type
Journal ArticlePublication Date
2012-06-15Keywords
DependovirusGenetic Vectors
Gene Therapy
Membrane Proteins
Muscle Proteins
Muscular Dystrophies, Limb-Girdle
Neurology
Neuroscience and Neurobiology
Metadata
Show full item recordAbstract
The dysferlinopathies comprise a group of untreatable muscle disorders including limb girdle muscular dystrophy type 2B, Miyoshi myopathy, distal anterior compartment syndrome, and rigid spine syndrome. As with other forms of muscular dystrophy, adeno-associated virus (AAV) gene transfer is a particularly auspicious treatment strategy, however the size of the DYSF cDNA (6.5 kb) negates packaging into traditional AAV serotypes known to express well in muscle (i.e. rAAV1, 2, 6, 8, 9). Potential advantages of a full cDNA versus a mini-gene include: maintaining structural-functional protein domains, evading protein misfolding, and avoiding novel epitopes that could be immunogenic. AAV5 has demonstrated unique plasticity with regards to packaging capacity and recombination of virions containing homologous regions of cDNA inserts has been implicated in the generation of full-length transcripts. Herein we show for the first time in vivo that homologous recombination following AAV5.DYSF gene transfer leads to the production of full length transcript and protein. Moreover, gene transfer of full-length dysferlin protein in dysferlin deficient mice resulted in expression levels sufficient to correct functional deficits in the diaphragm and importantly in skeletal muscle membrane repair. Intravascular regional gene transfer through the femoral artery produced high levels of transduction and enabled targeting of specific muscle groups affected by the dysferlinopathies setting the stage for potential translation to clinical trials. We provide proof of principle that AAV5 mediated delivery of dysferlin is a highly promising strategy for treatment of dysferlinopathies and has far-reaching implications for the therapeutic delivery of other large genes.Source
Grose WE, Clark KR, Griffin D, Malik V, Shontz KM, et al. (2012) Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer. PLoS ONE 7(6): e39233. doi:10.1371/journal.pone.0039233. Link to article on publisher's siteDOI
10.1371/journal.pone.0039233Permanent Link to this Item
http://hdl.handle.net/20.500.14038/37743PubMed ID
22720081Related Resources
Link to Article in PubMedRights
Copyright: © 2012 Grose et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0039233